Ruoying Yu

1.1k total citations
53 papers, 739 citations indexed

About

Ruoying Yu is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ruoying Yu has authored 53 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cancer Research, 20 papers in Pulmonary and Respiratory Medicine and 20 papers in Oncology. Recurrent topics in Ruoying Yu's work include Cancer Genomics and Diagnostics (21 papers), Lung Cancer Treatments and Mutations (15 papers) and Genetic factors in colorectal cancer (6 papers). Ruoying Yu is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), Lung Cancer Treatments and Mutations (15 papers) and Genetic factors in colorectal cancer (6 papers). Ruoying Yu collaborates with scholars based in China, United States and Canada. Ruoying Yu's co-authors include Maharaj K. Ticku, Yang Shao, C. J. Dickinson, Yi‐Long Wu, Qing Zhou, Zhihong Chen, Xu‐Chao Zhang, Xiaoxiao Peng, Xue Wu and Li Liu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ruoying Yu

50 papers receiving 721 citations

Peers

Ruoying Yu

ONCOL

PRM

CMN

Junyu Wang China

Tianfu Li China

Daniela Dreymueller Germany

Leah A. Owen United States

Craig Johnson United States

Lina Zhu China

Hongye Liu United States

Tatsuya Inoue Japan

Shu-Heng Jiang China

Hui Dong China

Junyu Wang China

Ruoying Yu

417 ×1.3

238 ×1.0

101 ×0.5

ONCOL

70 ×0.4

PRM

39 ×0.5

CMN

Citations per year, relative to Ruoying Yu Ruoying Yu (= 1×) peers Junyu Wang

Countries citing papers authored by Ruoying Yu

Since Specialization

Citations

This map shows the geographic impact of Ruoying Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruoying Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruoying Yu more than expected).

Fields of papers citing papers by Ruoying Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruoying Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruoying Yu. The network helps show where Ruoying Yu may publish in the future.

Co-authorship network of co-authors of Ruoying Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruoying Yu. A scholar is included among the top collaborators of Ruoying Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruoying Yu. Ruoying Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dong, Yuhan, et al.. (2025). HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis. npj Breast Cancer. 12(1). 9–9.

Gao, Yu, Yi Zhou, Kaihua Liu, et al.. (2024). Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients. Genomics. 116(2). 110808–110808. 3 indexed citations

Pu, Jun, Ruoying Yu, Qiuxiang Ou, et al.. (2023). Pan‐cancer molecular analysis of EGFR large fragment deletion in the Asian population. Cancer Medicine. 12(7). 8083–8088. 2 indexed citations

Wang, He, et al.. (2023). Electric vehicle dispatching strategy considering time cost and risk of operating distribution network. IET Energy Systems Integration. 5(4). 444–461. 2 indexed citations

Zhao, Xiaotian, Jingwen Liu, Yang Xu, et al.. (2022). Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer. Molecular Oncology. 16(20). 3689–3702. 5 indexed citations

Yu, Ruoying, Qiuxiang Ou, Hua Bao, et al.. (2022). Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population. Cancer Medicine. 12(5). 6009–6015. 3 indexed citations

Gan, Meifu, Chen Zhang, Yue Wang, et al.. (2022). Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients. Cancer Medicine. 11(21). 4070–4078. 6 indexed citations

Zhou, Ming, et al.. (2022). Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports. Journal of International Medical Research. 50(4). 3629155202–3629155202.

Zhu, Chunrong, Liangjun Zhu, Yanhong Gu, et al.. (2021). Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. Frontiers in Genetics. 12. 608742–608742. 9 indexed citations

10.

Zhang, Cheng, Zuhua Chen, Xiaoyi Chong, et al.. (2020). Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies. SHILAP Revista de lepidopterología. 10(8). e254–e254. 29 indexed citations

11.

Peng, Xiaoxiao, Ruoying Yu, Xue Wu, et al.. (2020). Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 8(1). e000376–e000376. 146 indexed citations

12.

Lu, Junliang, Ruoying Yu, Rui Liu, et al.. (2020). Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Cancer Medicine. 10(3). 933–943. 13 indexed citations

13.

Fan, Yun, Jinrong Qiu, Ruoying Yu, et al.. (2020). Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations. Molecular Oncology. 14(8). 1731–1739. 3 indexed citations

14.

Shen, Bo, Feixiang Wu, Jiazhou Ye, et al.. (2019). Crizotinib-Resistant MET Mutations in Gastric Cancer Patients are Sensitive to Type II Tyrosine Kinase Inhibitors. Future Oncology. 15(22). 2585–2593. 4 indexed citations

15.

Chen, Zhanhong, Tian Sun, Ziyan Yang, et al.. (2019). Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular Genetics & Genomic Medicine. 8(2). e1079–e1079. 25 indexed citations

16.

Eltringham‐Smith, Louise J., Ruoying Yu, Syed M. Qadri, et al.. (2019). Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy. Scientific Reports. 9(1). 13029–13029. 2 indexed citations

17.

Qin, Jing, Daxiong Zeng, Fajun Xie, et al.. (2019). Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response. Translational Cancer Research. 8(5). 2187–2191. 4 indexed citations

18.

Xu, Miao, June Li, Miguel A. D. Neves, et al.. (2018). GPIbα is required for platelet-mediated hepatic thrombopoietin generation. Blood. 132(6). 622–634. 50 indexed citations

19.

Yu, Ruoying, Meredith Hay, & Maharaj K. Ticku. (1996). Chronic neurosteroid treatment attenuates single cell GABAA response and its potentiation by modulators in cortical neurons. Brain Research. 706(1). 160–162. 32 indexed citations

20.

Yu, Ruoying & Maharaj K. Ticku. (1995). Effects of chronic pentobarbital treatment on the GABAA receptor complex in mammalian cortical neurons.. Journal of Pharmacology and Experimental Therapeutics. 275(3). 1442–1446. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact